Dasatinib is a medication used in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its chemical name is N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, its molecular formula is C22H26ClN7O2S, and its molecular weight is 488.01 g/mol. The CAS number for Dasatinib is 302962-49-8.
Top Ten Keywords from Google and Synonyms:
Health Benefits of Dasatinib: The primary health benefit of Dasatinib is its ability to treat chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. It has been shown to be effective in patients who have become resistant to other medications, such as imatinib.
Potential Effects of Dasatinib: Dasatinib works by inhibiting tyrosine kinase enzymes that are involved in the growth and spread of cancerous cells. This can slow the progression of the disease and may even lead to remission in some patients. Some studies have also suggested that Dasatinib may have anti-inflammatory properties and could be effective in treating autoimmune diseases such as rheumatoid arthritis.
Product Mechanism: The mechanism of action for Dasatinib involves inhibition of certain tyrosine kinase enzymes, particularly those involved in the BCR-ABL pathway that drives the growth and proliferation of leukemic cells. By blocking these enzymes, Dasatinib can help to slow the growth and spread of cancerous cells and may even lead to their destruction.
Safety: Dasatinib can have potentially serious side effects and should only be used under close medical supervision. It is contraindicated in pregnant women, as it could harm the developing fetus. Other potential side effects may include increased risk of infection, anemia, fatigue, and gastrointestinal problems.
Side Effects: Dasatinib can have a range of potential side effects, some of which can be serious or even life-threatening. These may include increased risk of infection, bone marrow suppression leading to low blood cell counts, liver toxicity, and cardiovascular events. Patients taking Dasatinib may also experience fatigue, nausea, diarrhea, and other gastrointestinal symptoms.
Dosing Information: Dasatinib dosing will vary depending on the specific condition being treated and the patient's individual needs. It is typically administered orally, and dosing instructions will be provided by the prescribing healthcare provider.
Conclusion: Dasatinib is a powerful medication that has shown promise in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. While it can have potentially serious side effects, it is an important tool in the fight against cancer and can help to improve quality of life for many patients. If you are considering Dasatinib treatment, it is important to discuss all potential risks and benefits with your healthcare provider and to carefully follow all dosing and monitoring instructions.
